Borad MJ, Droz Dit Busset M, Javle MM, Shaib WL, et al. A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01. Hepatology 2026 Oct 27. doi: 10.1097/HEP.0000000000001902.
PMID: 42937546